BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

OSI Pharmaceuticals, Inc. 

A Wholly-Owned Subsidiary of Astellas US LLC
One Bioscience Park Drive
Farmingdale  New York  11735  U.S.A.
Phone: 631-962-2000 Fax: 631-752-3880


SEARCH JOBS

About OSI Pharmaceuticals

OSI Pharmaceuticals, acquired by Astellas Pharma Inc. in 2010, is a leading biotechnology company focused on the discovery and development of high-quality, next-generation oncology products to both extend and improve the lives of cancer patients worldwide. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company. OSI serves as Astellas’ small molecule research arm and focuses on developing mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition in the development of cancer. OSI has a balanced pipeline of oncology drug candidates that includes both mechanism-based, gene-targeted therapies focused in the areas of signal transduction and apoptosis and next-generation cytotoxic chemotherapy agents. OSI discovered and developed Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology candidates in the R&D pipeline.

For additional information about the company, please visit www.astellas.us.

Company Contact Information
Maribeth Landwehr, Director
Corporate Communications

 Key Statistics


Email:
Ownership: Subsidiary

Web Site: OSI Pharmaceuticals, Inc.
Employees:
Symbol: OSIP
 



Industry
Biotechnology






 Company News
Astellas Pharma Inc. (YPH.BE) Shuts Down OSI Pharmaceuticals, Inc. (OSIP), Perseid in Restructuring of R&D Ops, Cuts 200 Jobs 5/14/2013 8:02:02 AM    More...
PanOptica, Inc. Appoints Colin Goddard, Former CEO of OSI Pharmaceuticals, Inc. (OSIP), to Board of Directors 4/1/2011 8:14:37 AM    More...
AVEO Pharmaceuticals, Inc. (AVEO) to Get $25 Million in Milestone Payments from OSI Pharmaceuticals, Inc. (OSIP) 12/1/2010 8:19:03 AM    More...
Astellas Pharma Inc. (YPH.BE) Keeping 90 OSI Pharmaceuticals, Inc. (OSIP) Jobs on Long Island 10/6/2010 7:19:48 AM    More...
OSI Pharmaceuticals, Inc. (OSIP) Announces the Results of its Offer to Purchase its 2% Convertible Notes and a Change in the Expiration Time of its Offer to Purchase its 3% Convertible Notes 7/14/2010 8:17:45 AM    More...
OSI Pharmaceuticals, Inc. (OSIP) Announces Occurrence of a Fundamental Change for Convertible Notes 6/18/2010 1:35:35 PM    More...
OSI Pharmaceuticals, Inc. (OSIP) Announces Occurrence of a Fundamental Change for Convertible Notes 6/10/2010 10:35:49 AM    More...
Astellas Pharma Inc. Completes Acquisition of OSI Pharmaceuticals, Inc. (OSIP) 6/9/2010 11:34:27 AM    More...
Astellas Pharma Inc. Announces Successful Completion of Tender Offer for Shares of OSI Pharmaceuticals, Inc. (OSIP) 6/8/2010 8:35:51 AM    More...
Astellas Pharma Inc. Gets 87% of OSI Pharmaceuticals, Inc. (OSIP) Shares in Sweetened Bid 6/3/2010 6:42:51 AM    More...
12345678910...

//-->